Commission Implementing Regulation (EU) 2025/787 of 24 April 2025 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1,4-dimethylnaphthalene, amidosulfuron, bentazone, bixafen, clomazone, fenoxaprop-P, fludioxonil, fluoxastrobin, flutolanil, fluxapyroxad, gibberellic acid, gibberellins, halauxifen-methyl, mecoprop-P, paraffin oil, penthiopyrad, pirimiphos-methyl, propamocarb, propyzamide, prothioconazole, rimsulfuron, sedaxane and sulfoxaflor

• CELEX: Implementing Regulation (EU) 2025/787
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

1.

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(a)

in the sixth column, expiration of approval, of row 57, Mecoprop-P, the date is replaced by ‘15 October 2027’;

(b)

in the sixth column, expiration of approval, of row 125, Rimsulfuron, the date is replaced by ‘15 August 2028’;

(c)

in the sixth column, expiration of approval, of row 154, Propamocarb, the date is replaced by ‘31 January 2027’;

(d)

in the sixth column, expiration of approval, of row 156, Pirimiphos-methyl, the date is replaced by ‘31 January 2027’;

(e)

in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘30 September 2026’;

(f)

in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘30 September 2026’;

(g)

in the sixth column, expiration of approval, of row 166, Fluoxastrobin, the date is replaced by ‘31 January 2027’;

(h)

in the sixth column, expiration of approval, of row 168, Prothioconazole, the date is replaced by ‘31 March 2027’;

(i)

in the sixth column, expiration of approval, of row 169, Amidosulfuron, the date is replaced by ‘30 November 2026’;

(j)

in the sixth column, expiration of approval, of row 182, Fenoxaprop-P, the date is replaced by ‘30 November 2026’;

(k)

in the sixth column, expiration of approval, of row 187, Flutolanil, the date is replaced by ‘15 June 2026’;

(l)

in the sixth column, expiration of approval, of row 232, Gibberellic acid, the date is replaced by ‘31 October 2026’;

(m)

in the sixth column, expiration of approval, of row 233, Gibberellins, the date is replaced by ‘31 October 2026’;

(n)

in the sixth column, expiration of approval, of row 295, Paraffin oil, the date is replaced by ‘30 November 2026’.

2.

Part B of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(a)

in the sixth column, expiration of approval, of row 24, Fluxapyroxad, the date is replaced by ‘31 October 2027’;

(b)

in the sixth column, expiration of approval, of row 43, Bixafen, the date is replaced by ‘31 October 2027’;

(c)

in the sixth column, expiration of approval, of row 48, Sedaxane, the date is replaced by ‘31 October 2027’;

(d)

in the sixth column, expiration of approval, of row 57, Penthiopyrad, the date is replaced by ‘31 October 2027’;

(e)

in the sixth column, expiration of approval, of row 68, 1,4-Dimethylnaphthalene, the date is replaced by ‘30 November 2027’;

(f)

in the sixth column, expiration of approval, of row 86, Halauxifen-methyl, the date is replaced by ‘5 January 2028’;

(g)

in the sixth column, expiration of approval, of row 88, Sulfoxaflor, the date is replaced by ‘18 January 2028’;

(h)

in the sixth column, expiration of approval, of row 120, Bentazone, the date is replaced by ‘31 October 2027’.

3.

In Part E of the Annex to Implementing Regulation (EU) No 540/2011, in the sixth column, expiration of approval, of row 9, Propyzamide, the date is replaced by ‘30 November 2027’.